Under a tenth of people who could benefit from obesity jabs like Wegovy can access them, caution the global health agency as it publishes its first recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"The new guidance recognises that obesity is a lifelong illness that can be addressed with holistic and lifelong treatment," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key hurdles to broad availability to the injections that can aid individuals in losing considerable body mass, notes the organization.
Skinny Jab Scarcity
Despite the present best projected scenario, the manufacturing of GLP-1 therapies could only cover about 100 million people – under 10% of eligible patients, as stated by the WHO.
The guideline urges governments and firms to expand availability, through strategies like patent sharing.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Operate
These medications replicate a natural hormone to delay gastric emptying, reduce hunger and enhance satiety so users eat less.
People commonly see weight reduction within a few weeks of beginning the regular doses.
Studies suggests patients may put most of the weight back on a year later of stopping the treatment, because their normal food cravings return.
Being carrying excess weight elevates your risk for experiencing medical conditions, like diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity impacts individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
